Trial · NCT07891182
VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study
NCT07891182, Phase 2, Not yet recruiting, University of Miami
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study. Trials, record NCT07891182. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07891182
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study
- NCT number
- NCT07891182
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 100 participants, estimated
- Lead sponsor
- University of Miami
- Conditions
- Glaucoma
- Interventions
- Aflibercept Injection, Ahmed Tube Surgery
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Intraocular pressure | Postoperative day 1, week 1, month 1, month 2, and month 3 | Intraocular pressure (IOP) measured by Goldmann applanation tonometry and reported in millimeters of mercury (mmHg). IOP represents the pressure within the eye and is assessed at each scheduled postoperative follow-up visit. |
| Secondary | Surgical failure | up to 6 months | Percentage of participants who meet any predefined surgical failure criterion, including: (1) intraocular pressure (IOP) \>21 mmHg and \<20% reduction from baseline on two consecutive visits after Month 3; (2) IOP \<5 mmHg on two consecutive visits after Month 3; (3) requirement for additional glaucoma surgery; or (4) loss of light perception vision. |
| Secondary | Medication Burden | Postoperative day 1, week 1, month 1, month 2, month 3, and month 6 | Medication burden assessed as the number of intraocular pressure (IOP) lowering medications used by participants daily. |
| Secondary | Hypertensive phase | Up to 3 months | Percentage of participants who experience a hypertensive phase, defined as intraocular pressure (IOP) greater than 21 mmHg, with or without glaucoma medications, during the first 3 months after surgery following a reduction of IOP to less than 22 mmHg during the first postoperative week. Hypertensive phase is a known risk factor for surgical failure. |
| Secondary | Treatment adverse events and serious treatment adverse events | Up to 6 months | Percentage of participants experiencing at least one treatment-related adverse event (AE) or serious adverse event (SAE). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07891182
GET https://conductscience.org/api/trials/v1/NCT07891182/registered